48 results
P
basal insulins
I/C
Neutral Protamine Hagedorn (NPH), ILPS, insulin glargine, detemir, degludec, insulin degludec, insulin degludec, 100 U/mL (IDeg-100), insulin degludec, 200 U/mL (IDeg-200), insulin lispro protamine (ILPS)
O
HbA1c reduction, weight change, hypoglycemic events
P
T1DM, T2DM
I/C
insulin degludec (IDeg), insulin glargine (IGla), insulin glargine 100 U/ml (IGla100), insulin glargine 300 U/ml (IGla300)
O
glycemic variability, fasting blood glucose (FBG), standard deviation of blood glucose for 24 h, mean of 24-h blood glucose, mean amplitude of glycemic excursion, coefficient of variation for 24 h, mean of daily differences, area under the glucose curve, M-value
P
North Americans
I/C
Exposure to outdoor air pollution, Low concentrations of particulate matter with an aerodynamic diameter of less than 2.5 μm (PM2.5) vs. current European Union (EU) Limit Values, U.S. Environmental Protection Agency (U.S. EPA), National Ambient Air Quality Standards (NAAQS), and/or World Health Organization (WHO) Air Quality Guideline values for PM2.5
O
Morbidity and mortality endpoints
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
White U.S. subjects
I/C
L28P variant, cognitively intact controls
O
AD risk
P
adult participants
I/C
resveratrol, no intervention
O
liver biomarkers
P
patients with nonalcoholic fatty liver disease (NAFLD)
I/C
measurement of paraoxonase 1 (PON1) activity, healthy controls
O
low PON1 activity in patients with NAFLD
P
ILD patients
I/C
Elevated KL-6 levels, Severe and progressive ILD groups, Non-progressive ILD group, Stable ILD, Survivors of ILD
O
Poor outcomes, Mortality, Progression of ILD
P
children, adolescents
I/C
incobotulinumtoxinA, placebo
O
safety endpoints
P
rice bran arabinoxylan compound
I/C
rice bran arabinoxylan compound, placebo
O
serum aspartate aminotransferase (AST) levels